T3D Therapeutics, Inc. has been selected by the Alzheimer’s Association to present pre-clinical results of T3D-959 at the upcoming Alzheimer’s Association International Conference (AAIC) in Washington, DC, July 18-23, 2015. The poster presentation will provide details of pre-clinical Alzheimer’s studies on the company’s lead once-a-day, oral drug candidate T3D-959, for which a Phase 2a clinical trial will be initiated in Q3 2015.The abstract entitled ” T3D-959; A Multi-Faceted Disease Remedial Drug Candidate for the Treatment of Alzheimer’s Disease,” has been selected for presentation in the session on Developing Topics, a session designed to bring the latest research findings in the field to AAIC attendees.
T3D Therapeutics Selected by the Alzheimer’s Association to Present Pre-Clinical Results of T3D-959 at the 2015 Alzheimer’s Association International Conference.
Jun 8, 2015 | News | 0 comments